Researchers at the Kimmel Cancer Center at Jefferson have demonstrated for the first time that the metabolic biomarker MCT4 directly links clinical outcomes with a new model of tumor metabolism that has patients "feeding" their cancer cells. Their findings were published online March 15 in Cell Cycle. To validate the prognostic value of the biomarker, a research team led by Agnieszka K. Witkiewicz, M.D., Associate Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, and Michael P. Lisanti, M.D., Ph.D., Professor and Chair of Stem Cell Biology and Regenerative Medicine at Jefferson, analyzed samples of patients with triple negative breast cancer, one of the most deadly of breast cancers, with fast-growing tumors that often affect younger women. A retrospective analysis of over 180 women revealed that high levels of the biomarker MCT4, or monocarboxylate transporter 4, were strictly correlated with a loss of caveolin-1 (Cav-1), a known marker of early tumor recurrence and metastasis in several cancers, including prostate and breast.
In the past decade, results from large prospective cohort studies and the Women's Health Initiative (WHI) randomized placebo-controlled hormone therapy trials have substantially changed thoughts about how estrogen alone and estrogen plus progestin influence the risk of breast cancer, according to a review published in the Journal of The National Cancer Institute. Although hormone therapy is currently used by millions of women for menopausal symptoms, there is still concern about hormone therapy-induced breast cancer risk. In addition, the effects of estrogen plus progestin vs estrogen alone on breast cancer are not completely understood. To compare the effects of estrogen alone vs those of estrogen plus progestin on breast cancer risk, Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and Garnet Anderson, Ph.
One in 10 people living in California's most productive agricultural areas is at risk for harmful levels of nitrate contamination in their drinking water, according to a report released today by the University of California, Davis. The report was commissioned by the California State Water Resources Control Board. "Cleaning up nitrate in groundwater is a complex problem with no single solution, " said Jay Lund, director of the UC Davis Center for Watershed Sciences and a report co-author. "This report should help inform discussions among people involved with drinking water, waste discharge, and agricultural issues, including various local and state government agencies." The report, "Addressing Nitrate in California's Drinking Water, " is the first comprehensive scientific investigation of nitrate contamination in the Tulare Lake Basin, which includes Fresno and Bakersfield, and the Salinas Valley, which includes Salinas and areas near Monterey.
A new investigational drug significantly reduced urinary cortisol levels and improved symptoms of Cushing's disease in the largest clinical study of this endocrine disorder ever conducted. Results of the clinical trial conducted at centers on four continents appear in the New England Journal of Medicine and show that treatment with pasireotide cut cortisol secretion an average of 50 percent and returned some patient's levels to normal. "Cushing's disease is a rare disorder, with three to five cases per million people. It can affect all ages and both genders but is most common in otherwise healthy young women, " says Beverly M.K. Biller, MD, of the Massachusetts General Hospital Neuroendocrine Unit, senior author of the study. "Often misdiagnosed, Cushing's is associated with a broad range of health problems - causing physical changes, metabolic abnormalities and emotional difficulties - and if not controlled, significantly increases patients' risk of dying much younger than expected.
A report entitled "STRAW+10" allows researchers and physicians to systematically and consistently identify the various reproductive stages women experience from adolescence to post-menopause. This support structure will help clinicians predict when a woman will enter menopause, as well as help them choose the most effective treatment options for menopausal symptoms and other associated conditions. The report is published in the journals Menopause, Journal of Clinical Endocrinology and Metabolism, Climacteric, and Fertility and Sterility. In September 2011, a group of US and international experts met in Washington, DC, in order to examine the most recent scientific data on the hormonal changes that distinguish reproductive aging in women, and to reach an agreement on defining the reproductive stages in a woman's life.